Paxlovid, COVID-19

Paxlovid does not significantly cut COVID hospitalization in older vaccinated adults, study finds
The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to new research by UCLA doctors. The findings, published Thursday in a research letter in the Journal of the American Medical Association,
Data suggest Paxlovid doesn't reduce severe COVID in older, vaccinated adults
The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the antiviral. The authors identified 1,620,884 Ontarians aged 65 to 74 years during the study period; most (87.5%) received at least 2 COVID-19 vaccines.
Paxlovid shows no clear benefit in preventing hospitalization, death among vaccinated seniors
COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that Paxlovid, while widely prescribed, did not significantly reduce COVID-19 hospitalizations or deaths in vaccinated older adults When Paxlovid prescriptions more than doubled for patients over 70,
Paxlovid May Not Significantly Benefit Vaccinated Seniors, Study Says
Still, Mafi says there aren't strong data on how Paxlovid affects the disease course in people who are vaccinated. His findings suggest that the benefits are about four times smaller than those reported by Pfizer.
Study: No large benefit from Paxlovid among COVID-vaccinated older adults
Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as previously thought, according to research published in JAMA.
Paxlovid shows limited benefit in older adults vaccinated against COVID-19, new research reveals
A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven efficacy in unvaccinated populations.
Paxlovid Is Less Effective In Older Vaccinated Covid Patients, Study Shows
Covid hospitalizations were not significantly reduced when adults used the antiviral pill, researchers find. Also, a nationwide study suggests estrogen may play a role in long covid, putting women at a higher risk.
Paxlovid's promise fades: Vaccinated seniors see minimal COVID-19 protection
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.
Rolling Out4h
What to know about the latest vaccine updates
COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
cidrap.umn13d
Data: Despite high risk of poor outcomes, only 1% of pregnant COVID patients given antiviral
The rate of antiviral prescriptions was 67% lower in pregnant than in nonpregnant women, including those with 1 or more ...
The Smartest Dividend Stocks to Buy With $1,000 Right Now
You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Verizon ...